EGFR and colorectal carcinoma: There is also a three-part Phase 1/2 study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of trametinib (GSK1120212) and dabrafenib (GSK2118436) when administered in combination with the anti-EGFR antibody panitumumab in subjects with BRAF V600E or V600K positive CRC (ClinicalTrials.gov number, NCT01750918).